fda glp-1 compounding enforcement october 2025 is moving to restrict mass-marketed compounded products that aren't FDA-approved, warning companies they can't market them as equivalent to approved drugs and signaling stronger to protect patients from unverified As GLP-1 weight-loss drugs surged

Join our upcoming webinar to discover how advanced LC-MS workflows are transforming GLP-1 peptide characterization

BMI Is GLP-1 right for me?* 24.9 or less No 25.0 29.9 Case-by-case 30.0 or above Likely *The above chart is not meant for medical diagnosis purposes

p<0.01) and waist circumference (MD 3.84cm

See safety info link on image.

In today's edition of The Readout, we have: What we know about JD Vance's health investments Fertility services for Casgevy patients Inflation cooling, biotech stocks heating up Get the rundown here

In the latest tranche of published warning letters, the US Food and Drug Administration (FDA) has continued to go after drugmakers for marketing glucagon-like peptide-1 (GLP-1) receptor agonists and similar medications without regulatory approval